Innova Captab Limited (NSE:INNOVACAP)

Market Cap	66.55B +63.8%
Revenue (ttm)	17.49B +34.5%
Net Income	1.54B +18.7%
EPS	26.92 +18.7%
Shares Out	57.22M
PE Ratio	43.21
Forward PE	31.82
Dividend	3.00 (0.26%)
Ex-Dividend Date	Jan 30, 2026

Volume	127,788
Open	1,097.40
Previous Close	1,092.00
Day's Range	1,086.30 - 1,174.80
52-Week Range	622.00 - 1,353.50
Beta	0.13
Analysts	Buy
Price Target	1,116.00 (-4.04%)
Earnings Date	Nov 13, 2026

About Innova Captab

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,600
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INNOVACAP

Financial Performance

In fiscal year 2026, Innova Captab's revenue was 16.30 billion, an increase of 31.06% compared to the previous year's 12.44 billion. Earnings were 1.41 billion, an increase of 9.87%.

Analyst Summary

According to 2 analysts, the average rating for INNOVACAP stock is "Buy." The 12-month stock price target is ₹1,116, which is a decrease of -4.04% from the latest price.

Price Target

₹1,116

(-4.04% downside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 12, 2026

Data Sources Report a data error